INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sensus Healthcare, Inc. - SRTSNEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sensus Healthcare, Inc. (“Sensus” or the “Company”) (
NASDAQ: SRTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Study Published in Dermatologic Therapy Shows Efficacy of Sensus Healthcare’s SRT Combined with Punch Excision to Treat Keloids
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces that a study published in Dermatologic Therapy demonstrates the safety and efficacy of the Company’s superficial radiotherapy (SRT) technology combined with punch excision to treat keloids.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sensus Healthcare, Inc. - SRTSNEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sensus Healthcare, Inc. (“Sensus” or the “Company”) (
NASDAQ: SRTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sensus Healthcare, Inc. - SRTSNEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sensus Healthcare, Inc. (“Sensus” or the “Company”) (
NASDAQ: SRTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
SENSUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Sensus Healthcare, Inc. on Behalf of Sensus Stockholders and Encourages Investors to Contact the FirmBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Sensus (SRTS) To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sensus Healthcare, Inc. - SRTSNEW YORK, Sept. 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sensus Healthcare, Inc. (“Sensus” or the “Company”) (
NASDAQ: SRTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Bragar Eagel & Squire, P.C. Is Investigating Avita, Coty, and Sensus and Encourages Investors to Contact the FirmNEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against AVITA Medical, Inc. (
NASDAQ:RCEL), Coty Inc. (
NYSE:COTY), and Sensus Healthcare, Inc. (
NASDAQ:SRTS). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sensus Healthcare, Inc. - SRTSNEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sensus Healthcare, Inc. (“Sensus” or the “Company”) (
NASDAQ: SRTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
SENSUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Sensus Healthcare, Inc. on Behalf of Sensus Stockholders and Encourages Investors to Contact the FirmBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Sensus (SRTS) To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sensus Healthcare, Inc. - SRTSNEW YORK, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sensus Healthcare, Inc. (“Sensus” or the “Company”) (
NASDAQ: SRTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sensus Healthcare, Inc. - SRTSNEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sensus Healthcare, Inc. (“Sensus” or the “Company”) (
NASDAQ: SRTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
SRTS Investors Have Opportunity to Join Sensus Healthcare, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sensus Healthcare, Inc. (“Sensus” or “the Company”) (
NASDAQ: SRTS) for violations of the securities laws.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sensus Healthcare, Inc. - SRTSNEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sensus Healthcare, Inc. (“Sensus” or the “Company”) (
NASDAQ: SRTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Sensus Healthcare Reports Second Quarter 2025 Financial Results
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and six months ended June 30, 2025.
Sensus Healthcare to Report Second Quarter 2025 Financial Results and Hold Business Update Conference Call on August 7
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the company will report financial results for the second quarter of 2025 on Thursday, August 7, 2025. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions.
Receipt of MDSAP Certification for Sensus Healthcare’s Full SRT Product Portfolio to Streamline and Accelerate International Sales Efforts
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces that its entire portfolio of superficial radiation therapy (SRT) systems – including the SRT-100®, SRT-100+™ and SRT-100 Vision™ – has received certification under the Medical Device Single Audit Program (MDSAP). This certification is expected to streamline the Company’s international regulatory efforts and enable faster commercial expansion into key global markets.
Sensus Healthcare Engages Radiology Oncology Systems (ROS) as Primary Distribution Partner for its SRT Systems to Radiation Oncologists
Sensus Healthcare, Inc. (Nasdaq: SRTS) (Sensus or the Company), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces it has entered into a strategic agreement with Radiology Oncology Systems (ROS) to serve as the Company’s primary distribution partner for the U.S. radiation oncology market. Under the terms of the agreement, ROS will be responsible for selling Sensus’s superficial radiotherapy (SRT) systems, including the SRT-100™ and the SRT-100 Vision™, to hospital-based radiation oncology departments and freestanding oncology centers nationwide.
